PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The decision to stop enrollment was due to strategic considerations and not due to any specific safety reasons or request from a regulatory authority.

Conditions

Breast Neoplasms
Prostate Neoplasms
Neoplasms, Squamous Cell
Melanoma
Mesothelioma
Pancreatic Neoplasms
Colorectal Neoplasms
Carcinoma, Renal Cell
Liver Neoplasms

Interventions

DRUG: PF-06952229
DRUG: Enzalutamide

Sponsor

Pfizer